Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 1:11 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 877 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Endocrine Clear all
Completed Phase 2 Interventional Results available

The Role of Hormones in Postpartum Mood Disorders

NCT00001481
View directory record Official record
Conditions
Postpartum Depression
Interventions
Estradiol, Placebo, Progesterone, leuprolide acetate
Drug · Other
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Nov 3, 2026, 1:11 PM EST
Recruiting Not applicable Interventional

Trial of Combined Obstetric Carrier Screening and Hereditary Cancer Screening

NCT07052266
View directory record Official record
Conditions
Hereditary Cancer Syndromes
Interventions
MyRisk Hereditary Cancer Test
Genetic
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Brooklyn, New York • New York, New York • Queens, New York
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Nov 3, 2026, 1:11 PM EST
Completed Not applicable Interventional Results available

Continuous Glucose Monitoring for Hyperglycemia in Critically Ill Patients

NCT05442853
View directory record Official record
Conditions
Hyperglycemia, Hypoglycemia, Critical Illness, Diabetes Mellitus
Interventions
Continuous glucose monitoring, Point of care glucose monitoring
Device
Lead sponsor
Malcom Randall VA Medical Center
Federal
Eligibility
18 Years to 89 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Nov 3, 2026, 1:11 PM EST
Completed No phase listed Observational Results available

Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer

NCT01896050
View directory record Official record
Conditions
Breast Cancer, Arthralgia, Obesity
Interventions
anastrozole, letrozole, exemestane, Tamoxifen
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Nov 3, 2026, 1:11 PM EST
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Development of Healthcare Transition for Patients With Congenital Adrenal Hyperplasia

NCT07611786
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
exposure to healthcare transition protocol
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
16 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Nov 3, 2026, 1:11 PM EST
Active, not recruiting No phase listed Observational

Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment

NCT05926024
View directory record Official record
Conditions
Breast Cancer
Interventions
Exercise Recall Patient Reported Outcomes, Health Behavior Questionnaire (HBQ)30 Patient Reported Outcomes, Functional Assessment of Cancer Therapy-General (FACT-G) Patient Reported Outcomes, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Patient Reported Outcomes, Patient Reported Outcomes PROMIS Cognitive Function (Short Form 8a), Patient Reported Outcomes Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12), Patient Reported Outcomes PROMIS, Patient Reported Outcomes FACT-Endocrine Symptoms, Patient Reported Outcomes Penn Arthralgia Aging Survey, Patient Reported Outcomes PRO-CTCAE (patient-reported CTCAE), p16 tumor suppressor gene
Behavioral · Diagnostic Test
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Nov 3, 2026, 1:11 PM EST
Active, not recruiting Phase 2 Interventional

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

NCT04762979
View directory record Official record
Conditions
Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer, PIK3CA Mutant Metastatic Breast Cancer
Interventions
Alpelisib, Fulvestrant, Aromatase inhibitor
Drug
Lead sponsor
Marina N Sharifi
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Chicago, Illinois • Omaha, Nebraska • Hershey, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Nov 3, 2026, 1:11 PM EST
Completed No phase listed Observational

Effect of Tamoxifen or an Aromatase Inhibitor on Estrogen Metabolism in Women Treated for Newly Diagnosed Breast Cancer

NCT00569543
View directory record Official record
Conditions
Breast Cancer
Interventions
high performance liquid chromatography, laboratory biomarker analysis, mass spectrometry, medical chart review
Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Rochester, Minnesota • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Nov 3, 2026, 1:11 PM EST
Terminated Phase 1 Interventional Results available

A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

NCT01296555
View directory record Official record
Conditions
Solid Cancers, Non-Hodgkin's Lymphoma
Interventions
Fulvestrant, GDC-0032, Letrozole, Midazolam
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
27
States / cities
Scottsdale, Arizona • Tucson, Arizona • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Nov 3, 2026, 1:11 PM EST
Recruiting Not applicable Interventional

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

NCT04251052
View directory record Official record
Conditions
Ovarian Carcinoma
Interventions
Bilateral Salpingectomy, Bilateral Salpingectomy with Oophorectomy, Biospecimen Collection, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Transvaginal Ultrasound, Ultrasound Imaging
Procedure · Other
Lead sponsor
NRG Oncology
Other
Eligibility
35 Years to 50 Years · Female only
Enrollment
1,956 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2047
U.S. locations
564
States / cities
Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 372 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Nov 3, 2026, 1:11 PM EST
Completed Not applicable Interventional

Identification and Treatment of Diabetes In Solid Organ Transplant Recipients

NCT02605200
View directory record Official record
Conditions
Complications of Transplanted Organs and Tissue
Interventions
Psychologist Support, Pediatric Certified Diabetes Educators (CDEs) Support
Behavioral
Lead sponsor
Emory University
Other
Eligibility
1 Year to 18 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Nov 3, 2026, 1:11 PM EST
Recruiting Phase 4 Interventional Accepts healthy volunteers

Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide

NCT06657209
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes, Type 2 Diabetes, Pre Diabetes
Interventions
Insulin resistance testing, OGTT, Fat biopsy, DXA scan, MRI, 1H-MRS, Tirzepatide, Pioglitazone
Procedure · Radiation · Drug
Lead sponsor
Stanford University
Other
Eligibility
30 Years to 70 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Palo Alto, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Nov 3, 2026, 1:11 PM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

PRediction Of Glycemic RESponse Study

NCT04881019
View directory record Official record
Conditions
Glycemic Response
Interventions
Continuous glucose monitoring
Device
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
18 Years and older
Enrollment
1,070 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Nov 3, 2026, 1:11 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Coagulation in Multiple Sclerosis

NCT01711255
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Bastyr University
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Kenmore, Washington
Source: ClinicalTrials.gov public record
Updated Jul 28, 2017 · Synced Nov 3, 2026, 1:11 PM EST
Completed Phase 4 Interventional Results available

TRUST: Lumos-T Safely RedUceS RouTine Office Device Follow-up

NCT00336284
View directory record Official record
Conditions
Patient Indicated for an ICD
Interventions
Home Monitoring, In-Office Conventional Follow-up
Other
Lead sponsor
Biotronik, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
108
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 87 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2010 · Synced Nov 3, 2026, 1:11 PM EST
Terminated Phase 2 Interventional Results available

Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)

NCT04738292
View directory record Official record
Conditions
ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Cancer
Interventions
Onapristone, Fulvestrant
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Nov 3, 2026, 1:11 PM EST
Not yet recruiting Not applicable Interventional

Treating PHPT With the nPulse™ Vybrance™ PE System

NCT07912892
View directory record Official record
Conditions
Primary Hyperparathyroidism
Interventions
Ultrasound-Guided Parathyroid Nanosecond Pulsed Field Ablation (nsPFA)
Device
Lead sponsor
Pulse Biosciences, Inc.
Industry
Eligibility
21 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Sarasota, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 1:11 PM EST
Recruiting Phase 2 Interventional

EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial

NCT06897488
View directory record Official record
Conditions
Breast Cancer
Interventions
Adjuvant Radiotherapy
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
60 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Nov 3, 2026, 1:11 PM EST
Completed Not applicable Interventional

Project MiNT: Assessing the Impact of Food & Video-Based Nutrition Education on Patients With Poorly Controlled Diabetes

NCT04264572
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Medically Tailored Meals, Tele-Medical Nutrition Therapy (tele-MNT)
Other · Behavioral
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Nov 3, 2026, 1:11 PM EST
Completed Not applicable Interventional Results available

An eHealth Intervention to Increase Depression Treatment Initiation and Adherence Among Veterans Referred for Mental Health Services

NCT05990075
View directory record Official record
Conditions
Depression
Interventions
self-monitoring
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 64 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Nov 3, 2026, 1:11 PM EST
Active, not recruiting Phase 1 Interventional

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

NCT03006172
View directory record Official record
Conditions
Breast Cancer, Solid Tumor
Interventions
Inavolisib, Fulvestrant, Letrozole, Palbociclib, Metformin, Trastuzumab, Pertuzumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Nov 3, 2026, 1:11 PM EST
Completed No phase listed Observational

Nodal Burden and Nodal Recurrence in Patients With Isolated Tumor Cells After Neoadjuvant Chemotherapy Treated With Axillary Dissection or Nodal Radiation: the OPBC-05/EUBREAST-14R/ICARO Study

NCT06464341
View directory record Official record
Conditions
Breast Cancer
Interventions
Observational study no intervention
Other
Lead sponsor
University Hospital, Basel, Switzerland
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Nov 3, 2026, 1:11 PM EST
Terminated Phase 2 Interventional Results available

Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients With Advanced Breast Cancer

NCT00525161
View directory record Official record
Conditions
Breast Cancer
Interventions
sorafenib
Drug
Lead sponsor
Suleiman Massarweh
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Nov 3, 2026, 1:11 PM EST
Completed No phase listed Observational

Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers

NCT00001246
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Schizophrenia, Attention Deficit Disorder With Hyperactivity
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
3 Years to 120 Years
Enrollment
4,276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1990
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 3, 2026, 1:11 PM EST